Conditions: Chronic Obstructive Pulmonary Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 84
Healthy volunteers: no

Brief summary:
Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: tetomilast intervention 2: placebo
Intervention descriptions: intervention 1: Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years. intervention 2: Placebo for 104 weeks (2 years)

Protocol document: